SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of sequencing systems, ...

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families. Through a ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced MiSeq™, a low-cost personal sequencing system that provides individual researchers a platform with rapid turnaround time, ...

Illumina, Inc. (NASDAQ:ILMN) today announced that HistoGenetics, the leader in high-resolution sequence-based human leukocyte antigen (HLA) testing services, has selected the MiSeq sequencing system ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that its MiSeq™Dx Sequencing System received the approval certificate from the China National Drug Administration (CNDA). This ...

With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (ILMN), a ...

NORTHAMPTON, MA / ACCESS Newswire / January 22, 2025 / Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 ...

The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, will empower customers to unlock powerful insights through an affordable, comprehensive solution that is simple to understand ...

Illumina's Aneesh Natarajan takes us on the journey Originally published on Illumina News Center NORTHAMPTON, MA / ACCESS Newswire / January 22, 2025 / Illumina recently launched the MiSeq i100 and ...